Guillain–Barré syndrome (GBS) outbreaks associated with endemic and epidemic infections have increased in recent decades, and the need for standard treatment guidelines is compelling. A new study presents data from a worldwide prospective observational registry, providing insights into current treatment practices and laying the foundations for future clinical trials.
This is a preview of subscription content, log in via an institution to check access.
References
Wachira, V. K., Peixoto, H. M. & de Oliveira, M. R. Systematic review of factors associated with the development of Guillain-Barré syndrome 2007–2017: what has changed? Trop. Med. Int. Health https://doi.org/10.1111/tmi.13181 (2019).
Chevret, S., Hughes, R. A. & Annane, D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst. Rev. 2, CD001798 (2017).
Hughes, R. A., Swan, A. V. & van Doorn, P. A. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst. Rev. 7, CD002063 (2012).
Overell, J. R., Hsieh, S. T., Odaka, M., Yuki, N. & Willison, H. J. Treatment for Fisher syndrome, Bickerstaff’s brainstem encephalitis and related disorders. Cochrane Database Syst. Rev. 1, CD004761 (2007).
Verboon, C. et al. Current treatment practice of Guillain-Barré syndrome. Neurology https://doi.org/10.1212/WNL.0000000000007719 (2019).
Hughes, R. A., Brassington, R., Gunn, A. A. & van Doorn, P. A. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst. Rev. 10, CD001446 (2016).
Walgaard, C. et al. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): protocol for a double-blind randomized, placebo-controlled clinical trial. J. Peripher. Nerv. Syst. 23, 210–215 (2018).
Korinthenberg, R., Schessl, J., Kirschner, J. & Mönting, J. S. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 116, 8–14 (2005).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
K.P. has received speaker honoraria and travel funding from Bayer Schering Pharma, Biogen Idec, Celgene, CSL Behring, Grifols and Novartis. R.G. serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Novartis and Teva Pharmaceutical Industries; has received speaker honoraria from Bayer Schering Pharma, Biogen Idec, Novartis and Teva Pharmaceutical Industries; serves as editor for Therapeutic Advances in Neurological Diseases and is on the editorial boards of Experimental Neurology and the Journal of Neuroimmunology; and receives research support from Bayer Schering Pharma, Biogen Idec, Genzyme, Merck Serono, Novartis and Teva Pharmaceutical Industries, none of which are related to this manuscript.
Rights and permissions
About this article
Cite this article
Pitarokoili, K., Gold, R. Heterogeneous GBS course requires standardized guidelines. Nat Rev Neurol 15, 561–562 (2019). https://doi.org/10.1038/s41582-019-0245-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-019-0245-6
- Springer Nature Limited
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.